Nicholas Company Inc. Raises Stake in Omnicell, Inc. $OMCL

Nicholas Company Inc. raised its stake in Omnicell, Inc. (NASDAQ:OMCL) by 6.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 104,488 shares of the company’s stock after buying an additional 5,868 shares during the quarter. Nicholas Company Inc.’s holdings in Omnicell were worth $3,072,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in Omnicell by 37.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock valued at $50,000 after buying an additional 458 shares in the last quarter. AlphaQuest LLC raised its position in Omnicell by 79.0% in the first quarter. AlphaQuest LLC now owns 6,400 shares of the company’s stock valued at $224,000 after purchasing an additional 2,824 shares during the period. New Age Alpha Advisors LLC purchased a new stake in Omnicell in the first quarter valued at $233,000. EntryPoint Capital LLC raised its position in Omnicell by 21.6% in the first quarter. EntryPoint Capital LLC now owns 6,671 shares of the company’s stock valued at $233,000 after purchasing an additional 1,184 shares during the period. Finally, EP Wealth Advisors LLC purchased a new stake in Omnicell in the first quarter valued at $245,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Price Performance

OMCL opened at $33.57 on Friday. The stock’s 50-day moving average price is $31.36 and its 200 day moving average price is $30.19. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $53.31. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of 67.14, a PEG ratio of 6.29 and a beta of 0.88.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, October 30th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The firm had revenue of $310.63 million for the quarter, compared to analyst estimates of $295.59 million. During the same quarter in the prior year, the company earned $0.56 EPS. Omnicell’s revenue was up 10.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.630-1.730 EPS. Q4 2025 guidance at 0.400-0.500 EPS. As a group, sell-side analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 3,880 shares of the stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $33.25, for a total transaction of $129,010.00. Following the transaction, the executive vice president owned 110,653 shares of the company’s stock, valued at approximately $3,679,212.25. This represents a 3.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.52% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on OMCL shares. Weiss Ratings restated a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. Benchmark lifted their target price on Omnicell from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday. Piper Sandler reduced their target price on Omnicell from $57.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 11th. Wall Street Zen downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Wells Fargo & Company lifted their target price on Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, July 21st. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $42.00.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.